1. Short title; table of contents (a) Short title This Act may be cited as the Cannabidiol and Marihuana Research Expansion Act . (b) Table of contents The table of contents for this Act is as follows: Sec. 1. Short title; table of contents. Sec. 2. Definitions. TITLE I—Registrations for marihuana research Sec. 101. Marihuana research applications. Sec. 102. Research protocols. Sec. 103. Applications to manufacture marihuana for research. Sec. 104. Adequate and uninterrupted supply. Sec. 105. Security requirements. Sec. 106. Prohibition against reinstating interdisciplinary review process for non-NIH funded researchers. TITLE II—Development of FDA-approved drugs using cannabidiol and marihuana Sec. 201. Medical research on cannabidiol. Sec. 202. Registration for the commercial production and distribution of Food and Drug Administration approved drugs. Sec. 203. Importation of cannabidiol for research purposes. TITLE III—Doctor-patient relationship Sec. 301. Doctor-patient relationship. TITLE IV—Federal research Sec. 401. Federal research. 2. Definitions In this Act— (1) the term appropriately registered means that an individual or entity is registered under the Controlled Substances Act ( 21 U.S.C. 801 et seq.) to engage in the type of activity that is carried out by the individual or entity with respect to a controlled substance on the schedule that is applicable to cannabidiol or marihuana, as applicable; (2) the term cannabidiol means— (A) the substance, cannabidiol, as derived from marihuana that has a tet­ra­hy­dro­can­nabinol level that is greater than 0.3 percent; and (B) the synthetic equivalent of the substance described in subparagraph (A); (3) the terms controlled substance , dispense , distribute , manufacture , marihuana , and practitioner have the meanings given such terms in section 102 of the Controlled Substances Act ( 21 U.S.C. 802 ), as amended by this Act